Market Cap $88.91M
!


Recently Updated
Corporate Spotlight
Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight
Actinogen reaches 100th participant milestone
Day | ||||||||
---|---|---|---|---|---|---|---|---|
Open | 2.8¢ | Day High | 2.8¢ | Day Low | 2.7¢ | |||
Daily Volume | 444532 |
Bids | Sellers | |||||
---|---|---|---|---|---|---|
Number | Price | Volume | Number | Price | Volume | |
1 | 2.7¢ | 530460 | 6 | 2.8¢ | 1529473 |
Directors & Senior Management
Dr. Steven Gourlay | Chief Executive Officer, Managing Director, Executive Director |
Mr. William Souter | Chief Financial Officer |
Ms. Cheryl Townsend | Vice President of Clinical Operations |
Mr. Michael Roberts | Head of Investor Relations and Comms |
Dr. Dana C. Hilt | Chief Medical Officer |
Ms. Fujun Li | Head of Manufacturing |
Mr. Andrew Udell | Chief Commercial Officer |
Mr. Peter Gordon Webse | Company Secretary |
Dr. Geoffrey E. D. Brooke | Non-Executive Chairman of the Board |
Mr. Malcolm John Mccomas | Non-Executive Director |
Mr. George Morstyn | Non-Executive Director |
Dr. Nicki J. Vasquez | Non-Executive Independent Director |
Data source: Refinitiv